Evolus Reports Improved Q1 Losses & Cash Flow, Secures New Credit Facility, but Faces Significant New Tariff Risks

summarizeSummary

Evolus reported improved Q1 2026 financial results with reduced losses and cash burn, secured a new $30M credit facility, and terminated its ATM program, but highlighted a new, significant risk of potential 100% tariffs on its key product, Jeuveau.

check_boxKey Events

• Improved Q1 Financial Performance

  The company reported a net loss of $10.7 million for Q1 2026, an improvement from a $18.9 million net loss in Q1 2025. Net cash used in operating activities decreased to $10.0 million from $15.6 million in the prior year period, and revenue increased by 6.7% to $73.1 million.

• New Revolving Credit Facility Secured

  Evolus entered into a new $30.0 million senior secured asset-based revolving credit facility on March 3, 2026, with an uncommitted accordion feature of up to an additional $10.0 million, enhancing its liquidity.

• ATM Offering Program Terminated

  The $50.0 million At-the-Market (ATM) Sales Agreement, established in March 2023, was terminated on May 1, 2026, with no shares having been sold under the program, removing a potential source of future dilution.

• Significant New Tariff Risk Identified

  The company disclosed a new risk of potential tariffs up to 100% on patented pharmaceuticals imported from South Korea, which could impact its Jeuveau product starting in September 2026, posing a material adverse effect on operations and financial condition.

auto_awesomeAnalysis

Evolus, Inc. filed its Q1 2026 10-Q, detailing improved financial performance with a reduced net loss and lower cash burn from operations compared to the prior year. The company reported a net loss of $10.7 million, an improvement from $18.9 million in Q1 2025, and operating cash flow improved to a $10.0 million use of cash from $15.6 million in the prior year. Revenue increased by 6.7% to $73.1 million. The company also strengthened its liquidity by securing a new $30.0 million senior secured asset-based revolving credit facility and terminated its $50.0 million At-the-Market (ATM) program without issuing any shares, removing a potential dilution overhang. However, the filing introduces a significant new risk factor: potential tariffs of up to 100% on patented pharmaceuticals imported from South Korea, which could apply to its key product, Jeuveau, starting in September 2026. This tariff risk represents a substantial potential headwind to future profitability and supply chain stability. Investors should monitor the impact of these potential tariffs and the company's ability to mitigate them.